Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide

Código QR

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide

Bryce C Simes, Gordon G MacGregor Alabama College of Osteopathic Medicine, Dothan, AL, USACorrespondence: Bryce C SimesAlabama College of Osteopathic Medicine, 445 Health Sciences Blvd., Dothan, AL 36303, USATel +1 205 904-504-8897Fax +1 205 334-699-2268Email simesbc@acom.eduAbstract: This comprehen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Simes BC, MacGregor GG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	SGLT2 inhibitors type 2 diabetes Canagliflozin Empagliflozin Dapagliflozin Ertugliflozin Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/a9a6921fe05e45a0b9d4d1b0f8d9704f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Santos Cavaiola T, et al.
Publicado: (2018)

DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS
por: Marina V. Shestakova
Publicado: (2019)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
por: Liu S, et al.
Publicado: (2019)

Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
por: Yaohui Jiang, et al.
Publicado: (2021)

Canagliflozin review – safety and efficacy profile in patients with T2DM
por: Jakher H, et al.
Publicado: (2019)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
por: Olga Yuryevna Sukhareva, et al.
Publicado: (2016)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh H, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
por: Muhammad Afzal, et al.
Publicado: (2021)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
por: A. V. Simanenkova, et al.
Publicado: (2021)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko Y, et al.
Publicado: (2018)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
por: Shen L, et al.
Publicado: (2021)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos I, et al.
Publicado: (2019)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
por: Schwartz SS, et al.
Publicado: (2016)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker CM, et al.
Publicado: (2016)

Empagliflozin in type 1 diabetes
por: Mathieu C, et al.
Publicado: (2019)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
por: Jadwiga Nessler
Publicado: (2021)

Is cancer incidence modified by SGLT2 inhibitors?
por: Lev M. Berstein
Publicado: (2019)

Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
por: Liu Y, et al.
Publicado: (2021)

Empagliflozin: a new strategy for nephroprotection in diabetes
por: Anton Ivanovich Korbut, et al.
Publicado: (2017)

Polypharmacology of clinical sodium glucose co‐transport protein 2 inhibitors and relationship to suspected adverse drug reactions
por: Karan Matharu, et al.
Publicado: (2021)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
por: Aurélie Pahud de Mortanges, et al.
Publicado: (2021)

Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice
por: Jiang YK, et al.
Publicado: (2019)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen T, et al.
Publicado: (2020)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Fan Yang, et al.
Publicado: (2020)

Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice
por: Chiang-Chi Huang, et al.
Publicado: (2021)

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
por: Kawarasaki S, et al.
Publicado: (2020)

12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus
por: Perna S, et al.
Publicado: (2018)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
por: A. M. Mkrtumyan, et al.
Publicado: (2021)

Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
por: Mei Qiu, et al.
Publicado: (2021)

In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia
por: Martina Hüttl, et al.
Publicado: (2021)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Steffen Pabel, et al.
Publicado: (2021)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies MJ, et al.
Publicado: (2017)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Masao Koike, et al.
Publicado: (2021)

Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
por: Nina A. Petunina, et al.
Publicado: (2016)

Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
por: Takahara M, et al.
Publicado: (2020)

Involvement of Intestinal Goblet Cells and Changes in Sodium Glucose Transporters Expression: Possible Therapeutic Targets in Autistic BTBR T<sup>+</sup>Itpr3<sup>tf</sup>/J Mice
por: Caterina Franco, et al.
Publicado: (2021)

Cetosis normoglicémica en adolescente con diabetes tipo 1 recibiendo insulina y dapaglifozina: Reporte de un caso
por: Pereyra A,Marcia, et al.
Publicado: (2017)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou I, et al.
Publicado: (2019)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
por: Munir KM, et al.
Publicado: (2016)

Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension
por: Silvie Hojná, et al.
Publicado: (2021)